Idiopathic pulmonary fibrosis (IPF), although a rare disease, is one of the most common interstitial lung diseases (ILDs). It is characterized by an irreversible loss of lung function, leading to high morbidity and mortality;\u00a0most patients die\u00a0within three to five\u00a0years following diagnosis. Interviewed experts contend that the etiology of IPF is unclear, but accumulating evidence suggests that it likely arises as a result\u00a0of epithelial injury followed by abnormal wound healing. Roche\u2019s Esbriet was the first disease-modifying therapy (DMT) approved for adults with mild to moderate IPF, followed soon after by Boehringer Ingelheim\u2019s Ofev\u2014setting the stage for fierce competition in the IPF therapy market. We explore this evolving space, analyzing the clinical and commercial outlook for current and emerging drugs\u00a0and identifying areas of pressing unmet need. We also assess different market scenarios in which a novel agent is approved as a monotherapy, as an add-on therapy, or both.<\/p>\n
QUESTIONS ANSWERED<\/strong><\/p>\n\n